Skip to main content
SpringerLink
Log in

SANAD-II-Studie - Teil 2: Generalisierte und unklassifizierbare Epilepsien

Erwartet: Levetiracetam unterliegt Valproat

  • Journal club
  • Published:
InFo Neurologie + Psychiatrie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Referenzen

  1. Marso, A et al. Lancet 2007; 369: 1016-26

  2. Elger, CE, Berkenfeld, R (geteilte Erstautorenschaft) et al. S1-Leitlinie 2017. Online: www.dgn.org/leitlinien

  3. Tomson T et al. Lancet Neurol 2018; 17: 530-8

Download references

Author information

Authors and Affiliations

  1. - Ärztllicher Direktor -, Epilepsiezentrum Kork, Landstr. 1, 77694, Kehl - Kork, Germany

    Bernhard J. Steinhoff

Authors
  1. Bernhard J. Steinhoff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bernhard J. Steinhoff.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Steinhoff, B. Erwartet: Levetiracetam unterliegt Valproat. InFo Neurologie 23, 28–29 (2021). https://doi.org/10.1007/s15005-021-2105-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15005-021-2105-3

Search

Navigation